Single-Dose Oritavancin in the Treatment of Acute Bacterial Skin Infections

2014302 citationsJournal Articlebronze Open Access

Authors

G. Ralph Corey · Duke Medical Center

Heidi Kabler · Sunrise Hospital & Medical Center

Purvi Mehra · Precision Research Institute

Sandeep K. Gupta · M.V. Hospital and Research Centre

J. Scott Overcash · Sharp Grossmont Hospital

Ashwin Porwal · Axis Multispecialty Hospital

Philip Giordano

Abstract

A single dose of oritavancin was noninferior to twice-daily vancomycin administered for 7 to 10 days for the treatment of acute bacterial skin and skin-structure infections caused by gram-positive pathogens. (Funded by the Medicines Company; SOLO I ClinicalTrials.gov number, NCT01252719.).

Topics & Keywords

Antimicrobial Resistance in Staphylococcus Bacterial Identification and Susceptibility Testing Streptococcal Infections and Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 370, Issue 23, pp. 2180-2190

DOI: 10.1056/nejmoa1310422

Field-Weighted Citation Impact: 24.29